Phaseline

Targets › FOLH1

FOLH1 (Glutamate carboxypeptidase 2): drug programs, companies and trials

75 programs from 56 companies in 135 trials: 61 Phase 2, 49 Phase 1, 20 Phase 3, 5 Phase 4; Oncology, Other; next expected readout Nov 2026.

Has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity. Has a preference for tri-alpha-glutamate peptides. (UniProt, Q04609)

Open in Phaseline: the race on FOLH1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NovartisLutetium Lu-177 Vipivotide Tetraxetan (AAA617)
Glutamate carboxypeptidase II binding agent
FOLH1Phase 4Prostate Cancer; Prostatic Neoplasms; Oligometastatic Prostate Cancer (OMPC); Metastatic Castration Resistant Prostate Cancer (mCRPC) …Dec 2026
Brigham and Women's Hospital18F-rhPSMA-7.3
PSMA-targeted radiopharmaceutical for PET imaging
FOLH1Phase 4Metastatic Prostate CancerDec 2026
M.D. Anderson Cancer CenterLu-177 PSMA
Lutetium-177 labeled PSMA-targeting radioligand
FOLH1Phase 4Lu-177 PSMASep 2028
OHSU Knight Cancer InstitutePiflufolastat F-18
PSMA-targeted PET imaging agent; F-18 labeled small molecule ligand targeting PSMA
FOLH1Phase 4Castration Resistant Prostate CancerSep 2028
NYU Langone HealthrhPSMA-7.3 (18F)
Prostate-specific membrane antigen (PSMA) targeting PET diagnostic agent
FOLH1Phase 3Prostate CancerNov 2026
Region Västerbotten[18F]PSMA-PET
PSMA-targeted PET imaging agent
FOLH1Phase 3Prostate CancerDec 2026
Clarity Pharmaceuticals64Cu-SAR-bisPSMA
64Cu-labeled anti-PSMA bisPSMA antibody for imaging
PSMA, FOLH1Phase 3Prostate Cancer; Prostatic Neoplasms, Castration-ResistantDec 2026
Telix Pharmaceuticals (Innovations)68Ga-PSMA-11
PSMA-targeting radioconjugate (Gallium-68 labeled PSMA ligand peptide conjugated via HBED-
FOLH1Phase 3PCAJan 2027
ABX advanced biochemical compounds[18F]PSMA-1007
PSMA-targeted PET imaging agent (fluorine-18 labeled small molecule)
FOLH1Phase 3Prostate CancerMar 2027
Johnson & Johnson (Janssen)JNJ-87189401
PSMA-targeted CD28 co-stimulatory agonist bispecific antibody
FOLH1Phase 3Metastatic Castration-resistant Prostatic Neoplasms; Prostatic NeoplasmsJun 2027
Jonsson Comprehensive Cancer CenterGallium Ga 68-labeled PSMA-11
PSMA-targeted PET imaging agent
FOLH1Phase 3Recurrent Prostate CarcinomaJul 2027
Stefan CarlssonIndividualized PSMA PET/CT Targeted Treatment
PSMA PET/CT imaging-guided radiotherapy using 68Ga and 18F radioligands targeting prostate
FOLH1Phase 3Prostate CancerOct 2027
Telix Pharmaceuticals (Innovations)177Lu-TLX591
Lutetium-177 labeled anti-PSMA antibody-drug conjugate
FOLH1Phase 3Metastatic Castration-resistant Prostate CancerDec 2027
Centre hospitalier de l'Université de Montréal (CHUM)18F-DCFPyL
PSMA-targeted PET tracer
FOLH1Phase 3Prostate CancerDec 2028
University of Alberta18F-PSMA-1007
PSMA-targeting PET tracer
FOLH1Phase 3Prostate CancerDec 2028
AstraZenecaActinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265])
alpha-emitting radioimmunotherapy targeting PSMA (Folate Hydrolase 1), anti-PSMA targeting
FOLH1Phase 3Metastatic Castration-resistant Prostate Cancer; Metastatic Prostate CancerJun 2029
Curium USCopper Cu 64 PSMA I&T
Cu-64 labeled PSMA-targeting radiopharmaceutical for PET imaging
FOLH1Phase 3Prostate Cancer–
Australian and New Zealand Urogenital and Prostate Cancer Trials GroupLu-PSMA (177Lutetium-PSMA-617)
Radiopharmaceutical targeting PSMA with lutetium-177 emitter
FOLH1Phase 2Metastatic Castration-Resistant Prostate CancerDec 2026
University Hospital TuebingenCC-1
Bispecific antibody targeting PSMA and CD3
FOLH1, CD3EPhase 2Prostate Cancer; Castration-Resistant Prostatic Cancer; Prostate Cancer RecurrentDec 2026
Martin T. King, MD, PhDPSMA PET/CT-guided SBRT with focal microboost
PSMA PET/CT imaging to guide stereotactic body radiation therapy with focal microboost bas
FOLH1Phase 2Intermediate Risk Prostate CancerDec 2026
Fusion PharmaceuticalsFPI-2265
Ac-225-labeled PSMA-targeting small molecule (targeted alpha therapy)
PSMA, FOLH1Phase 2Metastatic Castration Resistant Prostate Cancer; Metastatic Castration-resistant Prostate CancerDec 2026
Centre de recherche du Centre hospitalier universitaire de Sherbrooke68Ga-PSMA
PSMA-targeting radiopharmaceutical for PET imaging
FOLH1Phase 2Upper Digestive Tract CancerDec 2026
Novartis[177Lu]Lu-PSMA-617
PSMA-targeted radioligand therapy with lutetium-177
FOLH1, GRPRPhase 2Metastatic Castration-Resistant Prostate Cancer (mCRPC); Metastatic Neuroendocrine Prostate Cancer; Metastatic Castration-resistant Prostate CancerJan 2027
Medical University of Vienna[177Lu]Lu-PSMA I&T
177Lu-labeled PSMA radioligand for targeted radiotherapy
FOLH1Phase 2Prostate Cancer Recurrent; Prostate CancerJan 2027
First Affiliated Hospital of Fujian Medical University68Ga-PSMA-CYC
PSMA-targeting radiotracer (gallium-68 labeled)
FOLH1Phase 2Prostate Cancer (Adenocarcinoma); Prostate CAFeb 2027
Ebrahim S DelpassandLutetium-177-PSMA-617 (PLUVICTO)
PSMA-targeted radioligand therapy (beta-emitting radionuclide conjugate)
FOLH1Phase 2Metastatic Castration-Resistant Prostate CancerApr 2027
Icahn School of Medicine at Mount SinaiFlotufolastat F18
PSMA-targeted radiotracer
FOLH1Phase 2Prostatic NeoplasmsMay 2027
Centre hospitalier de l'Université de Montréal (CHUM)[18F]DCFPyL
PSMA-targeted PET imaging agent
FOLH1Phase 2Prostate CancerMay 2027
Memorial Sloan Kettering Cancer Center68Ga-HBED-iPSMA
PSMA-targeting PET imaging agent
FOLH1Phase 2Prostate AdenocarcinomaJun 2027
Clinton BahlerOTL78 (zopocianine)
PSMA-targeted fluorescent dye
FOLH1Phase 2Prostate Cancer SurgeryJul 2027
Convergent TherapeuticsAc-225 rosopatamab tetraxetan
PSMA-directed radioantibody conjugated to Ac-225
FOLH1Phase 2PSMA PET-Positive Castration-Resistant Prostate CancerAug 2027
AdventHealth18F-rhPSMA-7.3 (Posluma)
PSMA-targeted PET imaging agent
FOLH1Phase 2Prostate Cancer (Post Prostatectomy)Sep 2027
H. Lee Moffitt Cancer Center and Research InstitutePSMA-617
PSMA-targeted radioligand therapy (lutetium-177 conjugate)
FOLH1Phase 2Metastatic Castration-resistant Prostate CancerSep 2027
Weill Medical College of Cornell UniversityGallium-68 labeled PSMA-HBED-CC
Gallium-68 labeled prostate-specific membrane antigen (PSMA) PET tracer
FOLH1Phase 2Prostate CancerDec 2027
Centre hospitalier de l'Université de Montréal (CHUM)177Lutetium-PSMA
PSMA-targeted radioligand therapy
FOLH1Phase 2Prostate Cancer Metastatic Castration-ResistantMay 2028
Emory University18F-rhPSMA-7.3
Fluorine-18 labeled radiohybrid PSMA-7.3 imaging agent targeting PSMA
FOLH1Phase 2Prostate AdenocarcinomaJul 2028
Mayo ClinicGa-68 PSMA-11
PSMA-targeted PET imaging agent
FOLH1Phase 2WHO Grade 3 GliomaJul 2028
University of WashingtonLutetium 177Lu-PSMA-617
Lutetium-177 labeled prostate-specific membrane antigen targeted radiopharmaceutical
FOLH1Phase 2Castration-Resistant Prostate CarcinomaSep 2028
Emory UniversityFlotufolastat F-18
PSMA-targeted radiotracer; F-18 radiolabeled PSMA-targeting peptide
FOLH1Phase 2Prostate CarcinomaDec 2028
Hackensack Meridian HealthLu-177-PSMA-617
Lutetium-177 labeled PSMA-targeted radioligand
FOLH1Phase 2Prostate AdenocarcinomaMar 2029
Emory UniversityGallium Ga68-labeled PSMA-11
Radiolabeled PSMA-targeting tracer for PET imaging
FOLH1Phase 2Prostate AdenocarcinomaMay 2030
Akiva MintzPiflufolastat F18
PSMA-targeting PET imaging agent
FOLH1Phase 2Healthy VolunteerJun 2030
University of FloridaFlotufolastat F 18
PSMA-targeted PET imaging agent
FOLH1Phase 2ProstateJul 2030
University of WashingtonGallium Ga 68 Gozetotide
68Ga-labeled PSMA ligand; radiotracer targeting prostate-specific membrane antigen (PSMA)
FOLH1Phase 2Biochemically Recurrent Prostate CarcinomaJul 2030
Jonsson Comprehensive Cancer CenterActinium Ac 225 Vipivotide Tetraxetan
Alpha-emitting radionuclide targeting PSMA (prostate-specific membrane antigen) with radio
FOLH1Phase 2Oligometastatic Prostate AdenocarcinomaOct 2030
Jonsson Comprehensive Cancer CenterLutetium Lu-177 PNT2002
177Lu-labeled PSMA-targeting radiopharmaceutical
FOLH1Phase 2Oligometastatic Prostate CarcinomaSep 2032
Jonsson Comprehensive Cancer CenterFlotufolastat F 18
PSMA-targeting PET imaging agent
FOLH1Phase 2Prostate CarcinomaOct 2035
Columbia University18F-DCFPyL
PSMA-targeted PET imaging agent (fluorinated prostate-specific membrane antigen targeting)
FOLH1Phase 2Prostatic Neoplasms–
Royal Marsden NHS Foundation Trust68Ga-PSMA
PSMA-targeting PET imaging agent
FOLH1Phase 2Malignant Melanoma–
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAl18F-PSMA-BCH
18F-labeled PSMA-targeting radiopharmaceutical for PET/CT imaging
FOLH1Phase 2Malignancy–
Hoag Memorial Hospital PresbyterianDCFPyL
PSMA-specific PET tracer
FOLH1Phase 2Prostate Cancer–
Jules Bordet InstituteLutetium-177 PSMA
Lutetium-177 radiolabelled PSMA ligand for targeted radionuclide therapy
FOLH1Phase 2TNBC - Triple-Negative Breast Cancer–
University of Texas Southwestern Medical Center68-Ga PSMA11 (Illucix)
PSMA-targeting PET imaging agent
FOLH1Phase 1Prostate AdenocarcinomaNov 2026
Shanghai Changzheng HospitalPSMA-UCAR T (BRL-302)
Universal CAR-T cell therapy targeting PSMA
FOLH1Phase 1Metastatic Prostate CancerNov 2026
The Affiliated Hospital of Xuzhou Medical UniversityPSMA-targeted CAR-T cells
anti-PSMA CAR-T cell therapy
FOLH1Phase 1ImmunotherapyNov 2026
Peter MacCallum Cancer Centre, AustraliaLutetium-177 PSMA-I&T
Prostate-specific membrane antigen (PSMA) targeted radioligand therapy with lutetium-177
FOLH1Phase 1Metastatic Castration-resistant Prostate CancerDec 2026
Instituto do Cancer do Estado de São Paulo177Lu-PSMA-I&T
Lutetium-177 labeled small molecule targeting prostate-specific membrane antigen (PSMA); r
FOLH1Phase 1Prostate Cancer (Adenocarcinoma)Dec 2026
Weill Medical College of Cornell University225Ac-J591
Alpha-emitter radiopharmaceutical; Actinium-225 conjugated to anti-PSMA antibody J591
PSMA, FOLH1Phase 1Prostate CancerDec 2026
M.D. Anderson Cancer Center177Lu rhPSMA-10.1
Lutetium-177-labeled recombinant human PSMA-targeting radiopharmaceutical for theranostic
FOLH1Phase 1Prostate CancerDec 2026
Johnson & Johnson (Janssen)ARX517
anti-PSMA antibody-drug conjugate with microtubule-disrupting toxins
FOLH1Phase 1Metastatic Prostate CancerDec 2026
Endocyte225Ac-PSMA-617
alpha-emitting radiopharmaceutical targeting PSMA
FOLH1Phase 1Prostatic Neoplasms, Castration-ResistantJan 2027
Osaka UniversityPSW-1025
PSMA-targeted alpha therapy labeled with Astatine-211 (At-211)
FOLH1Phase 1Prostate CancerMar 2027
Thomas HopeActinium-225 Prostate-Specific Membrane Antigen 617
PSMA-targeting radioligand therapy with actinium-225
FOLH1Phase 1Prostate CancerApr 2027
VitsGen Therapeutics177Lu-PSMA-VG01
PSMA-targeting radioligand (lutetium-177 labeled)
FOLH1Phase 1PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)May 2027
Memorial Sloan Kettering Cancer Centerengineered autologous T cells (CAR-T cells targeting PSMA)
Chimeric antigen receptor (CAR) T cells directed against prostate-specific membrane antige
FOLH1Phase 1Prostate CancerJun 2027
Memorial Sloan Kettering Cancer Center[68Ga]PSMA
68Gallium-labeled PSMA radiotracer for PET/CT imaging
FOLH1Phase 1Bladder CancerSep 2027
Memorial Sloan Kettering Cancer Center(64Cu)-NOTA-PSMAi-PEG-Cy5.5-C' dot tracer
PSMA-targeting radiotracer with copper-64 and fluorescent Cy5.5 dye for PET/MRI and optica
FOLH1Phase 1Prostate CancerNov 2027
Memorial Sloan Kettering Cancer Center89Zr-DFO-PSMAi-PEG-Cy5.5-C' dots
PSMA-targeting radiotracer with zirconium-89 and fluorescent Cy5.5 dye for PET/MRI and opt
FOLH1Phase 1Prostate CancerNov 2027
T.O.A.D. OncologyTD001
anti-PSMA antibody-drug conjugate
FOLH1Phase 1Metastatic Castration-Resistant Prostatic CancerMar 2028
Emory UniversityLutetium Lu 177 PSMA-10.1
PSMA-targeting radioligand therapy delivering beta radiation to PSMA-expressing tumor cell
FOLH1Phase 1Biochemically Recurrent Prostate CarcinomaApr 2028
Rabin Medical CenterTb-PSMA-I&T
Terbium-161 PSMA-targeting radiopharmaceutical emitting beta particles and Auger electrons
FOLH1Phase 1High Risk Prostate CancerAug 2028
National Taiwan University Hospital161Tb-PSMA-I&T
PSMA-targeted radioligand therapy using Terbium-161 (Auger electron emitter)
FOLH1Phase 1Metastatic Castration Resistant Prostate Cancer (mCRPC)Dec 2030
Novartis[225Ac]Ac-PSMA-R2
Alpha-emitting radiopharmaceutical targeting PSMA; 225Ac-labeled PSMA ligand
FOLH1Phase 1Prostate CancerMar 2031
University College, LondonActinium (225Ac) rhPSMA-10.1
Alpha-emitting radiopharmaceutical targeting PSMA
FOLH1Phase 1Metastatic Castration-resistant Prostate CancerMar 2031
Five Eleven PharmaGa-68 P16-093
PSMA-targeted PET imaging agent (gallium-68 labeled PSMA ligand)
FOLH1Phase 1Prostate Cancer Recurrent–

Conditions

Prostate Cancer (32) Metastatic Castration-resistant Prostate Cancer (9) Prostatic Neoplasms (8) Metastatic Prostate Cancer (6) Prostate Adenocarcinoma (5) Castration-Resistant Prostate Carcinoma (4) Metastatic Castration Resistant Prostate Cancer (mCRPC) (3) Metastatic Castration-Resistant Prostate Cancer (3) Prostate Carcinoma (3) Prostate Cancer Recurrent (3) Metastatic Castration-Resistant Prostate Cancer (mCRPC) (2) Prostate Cancer Metastatic (2)

Modalities

small molecule (51), mixed (9), protein or peptide (5), other (2), antibody (1)

Companies

Memorial Sloan Kettering Cancer Center (5) Emory University (4) Jonsson Comprehensive Cancer Center (4) Novartis (3) Centre hospitalier de l'Université de Montréal (CHUM) (3) Weill Medical College of Cornell University (2) University of Washington (2) Johnson & Johnson (Janssen) (2) Telix Pharmaceuticals (Innovations) (2) M.D. Anderson Cancer Center (2) OHSU Knight Cancer Institute (1) Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) Martin T. King, MD, PhD (1) Columbia University (1) Medical University of Vienna (1) NYU Langone Health (1) Ebrahim S Delpassand (1) Centre de recherche du Centre hospitalier universitaire de Sherbrooke (1) Thomas Hope (1) Royal Marsden NHS Foundation Trust (1)

Related targets

PSMA (3) GRPR (1) CD3E (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.